The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
Subscribe!
Welcome to season 3 of the MDS Professional Report. We look forward to your feedback!
Episode 2:
Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with a special focus on Higher-risk MDs, and providing their take home messages.
Welcome to season 3 of the MDS Professional Report. We look forward to your feedback!
Episode 1:
Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (ASH) 2023 meeting. They provide some data on luspatercept, imetelstat, roxodustat and Ker-050.
Welcome to season 2 of the MDS Professional Report. We look forward to your feedback!
Episode 4:
Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss issues related to RBC transfusions, the hemoglobin threshold for transfusion and related quality of life issues
Prof. Akiko Shimamura (Harvard Medical School, Boston), Guillermo Sanz (Valencia) and Moshe Mittelman (Tel Aviv) discuss the features of childhood MDS, and the differences between pediatric and adult primary MDS.
Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, follow up and prediction of treatment. They also discuss the role of the newly approved luspatercept in the treatment of anemic transfusion-dependent patients with lower-risk MDS
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel, discuss several important presentations from the recent 2021 ASH meeting.
